• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Will Johnson & Johnson Be a Better Buy After Spinning Off Its Consumer Business?

cafead

Administrator
Staff member
  • cafead   Jan 20, 2022 at 11:42: AM
via
  • J&J is simplifying its business through a spinoff that should also ease some of its headaches.
  • All three of its main segments are profitable and growing sales, but at much different rates.

article source
 

<